(S/R)-ethyl 3-(4-hydroxyphenyl)-2-isopropoxy-propionate | 325827-31-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (S/R)-ethyl 3-(4-hydroxyphenyl)-2-isopropoxy-propionate
• 英文别名: ethyl 3-(4-hydroxyphenyl)-2-isopropoxypropanoate；ethyl 3-(4-hydroxyphenyl)-2-propan-2-yloxypropanoate
• CAS: 325827-31-4
• 化学式: C₁₄H₂₀O₄
• 分子量: 252.31
• InChiKey: LUSCFTYKFUSUBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S/R)-ethyl 3-(4-hydroxyphenyl)-2-isopropoxy-propionate 、 (E)-3-([1,1'-biphenyl]-4-yl)but-2-en-1-ol 以70%的产率得到(S/R)-ethyl 3-[4-(3-biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-isopropoxy-propionate
  参考文献：
  名称：

  Compounds, their preparation and use

  摘要：

  本发明涉及一般式(I)的化合物。 这些化合物在治疗和/或预防由核受体介导的疾病中具有用途，特别是过氧化物酶体增殖激活受体（PPAR）。

  公开号：

  US06555577B1
• 作为产物：
  描述：

  Ethyl 3-(4-phenylmethoxyphenyl)-2-propan-2-yloxyprop-2-enoate 在 palladium 10% on activated carbon 氢气 作用下， 以 乙醇 为溶剂， 反应 5.0h， 生成 (S/R)-ethyl 3-(4-hydroxyphenyl)-2-isopropoxy-propionate
  参考文献：
  名称：

  EP1380562

  摘要：

  公开号：

文献信息

• Process for the preparation of substituted 3-phenyl-propanoic acid esters and substituted 3-phenyl-propanoic acids
  申请人：——

  公开号：US20030008361A1

  公开（公告）日：2003-01-09

  The present invention relates to a process comprising hydrolysis or trans esterification of one of the two enantiomeric forms of a racemic or enantiomerically enriched ester of formula I or IV by a higher rate than the other by an enzyme to give an ester and a acid (III) or two different esters (V) and (VI) with different R groups both with increased enantiomeric purity and a esterification process of a racemic or enantiomerically enriched acid (VII) by an enzyme to give an ester and an acid both with increased enantiomeric purity.

  本发明涉及一种过程，包括通过酶催化作用使公克混合物或对映富集的酯化合物I或IV的两种对映异构体中的一种水解或酯交换速率高于另一种，从而得到具有提高对映纯度的酯和酸III或具有不同R基团的两种不同酯V和VI，以及通过酶催化作用酯化公克混合物或对映富集的酸VII，从而得到具有提高对映纯度的酯和酸。
• Carboxylic acid derivative and salt thereof
  申请人：——

  公开号：US20040102634A1

  公开（公告）日：2004-05-27

  The present invention provides a novel carboxylic acid compound, a salt thereof or a hydrate of them useful as an insulin sensitizer, and a medicament comprising the compound as an active ingredient. That is, the present invention provides a carboxylic acid compound represented by the following formula, a salt thereof, an ester thereof or a hydrate of them. 1 Wherein R 1 represents a hydrogen atom, hydroxyl group, halogen, carboxyl group, or a C 1-6 alkyl group etc., each of which may have one or more substituents; L represents a single bond, or a C 1-6 alkylene group, a C 2-6 alkenylene group or a C 2-6 alkynylene group, each of which may have one or more substituents; M represents a single bond, or a C 1-6 alkylene group, a C 2-6 alkenylene group or a C 2-6 alkynylene group, each of which may have one or more substituents; T represents a single bond, or a C 1-3 alkylene group, a C 2-3 alkenylene group or a C 2-3 alkynylene group, each of which may have one or more substituents; W represents a carboxyl group; 2 represents a single bond etc.; X represents a single bond, oxygen atom, a group represented by —NR X1 CQ 1 O— (wherein Q 1 represents an oxygen atom or sulfur atom; and R X1 represents a hydrogen atom, formyl group, or a C 1-6 alkyl group etc., each of which may have one or more substituents), —OCQ 1 NR X1 — (wherein Q 1 and R X1 are as defined above), —CQ 1 NR X1 O— (wherein Q 1 and R X1 are as defined above), ONR X1 CQ 1 — (wherein Q 1 and R X1 are as defined above), -Q 2 SO 2 — (wherein Q 2 is an oxygen atom or —NR X10 — (wherein R X10 represents a hydrogen atom, formyl group, or a C 1-6 alkyl group etc., each of which may have one or more substituents)) or —SO 2 Q 2 - (wherein Q 2 is as defined above), (wherein, provided that R X2 and R X3 , and/or R X4 and R X5 may together form a ring, Q 3 and Q 4 are the same as or different from each other and each represents an oxygen atom, (O)S(O) or NR X10 (wherein NR X10 is as defined above)); Y represents a 5- to 14-membered aromatic group etc., which may have one or more substituents and one or more hetero atoms; and the ring Z represents a 5- to 14-membered aromatic group which may have 0 to 4 substituents and one or more hetero atoms, and wherein part of the ring may be saturated.

  本发明提供了一种新型的羧酸化合物、其盐或水合物，作为胰岛素增敏剂，并且提供了一种包含该化合物作为活性成分的药物。即，本发明提供了由以下式表示的羧酸化合物、其盐、酯或水合物。其中，R1表示氢原子、羟基、卤素、羧基或C1-6烷基等，每个都可以有一个或多个取代基；L表示单键，或C1-6烷基、C2-6烯基或C2-6炔基等，每个都可以有一个或多个取代基；M表示单键，或C1-6烷基、C2-6烯基或C2-6炔基等，每个都可以有一个或多个取代基；T表示单键，或C1-3烷基、C2-3烯基或C2-3炔基等，每个都可以有一个或多个取代基；W表示羧基；2表示单键等；X表示单键、氧原子、由—NRX1CQ1O—表示的基团（其中，Q1表示氧原子或硫原子；RX1表示氢原子、甲酰基或C1-6烷基等，每个都可以有一个或多个取代基）、由—OCQ1NRX1—表示的基团（其中，Q1和RX1如上所定义）、由—CQ1NRX1O—表示的基团（其中，Q1和RX1如上所定义）、由ONRX1CQ1—表示的基团（其中，Q1和RX1如上所定义）、由-Q2SO2—表示的基团（其中，Q2是氧原子或—NRX10—（其中，RX10表示氢原子、甲酰基或C1-6烷基等，每个都可以有一个或多个取代基））或由—SO2Q2—表示的基团（其中，Q2如上所定义），（其中，假设RX2和RX3，以及RX4和RX5可以共同形成环，Q3和Q4相同或不同，每个表示氧原子、（O）S（O）或NRX10（其中，NRX10如上所定义））；Y表示5-至14-成员芳香基等，可以有一个或多个取代基和一个或多个杂原子；环Z表示5-至14-成员芳香基，可以有0至4个取代基和一个或多个杂原子，其中环的一部分可以饱和。
• Peroxisome proliferator activated receptor agonists
  申请人：Gibson Ann Tracey

  公开号：US20050020652A1

  公开（公告）日：2005-01-27

  The present invention is directed to compounds represented by the following structural Formula (I), (a) R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C 1 -C 8 alkyl, aryl-C 0-4 -alkyl, heteroaryl-C 0-4 -alkyl, C 6 cycloalkylaryl-C 0-2 -alkyl, and —CH 2 —C(O)—R17-R18, wherein R17 is O or NH and R18 is optionally substituted benzyl; (b) R2 is selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkenyl, aryl-C 0-4 -alkyl, heteroaryl-C 0-4 -alkyl, C 1 -C 4 alkyl sulfonamide, C 1 -C 4 alkyl amide, OR10 and C 3 -C 6 cycloalkyl; (c) W is O or S; (d) X is an optionally substituted C 1 -C 5 alkylene linker wherein one carbon atom of the linker may optionally be replaced with O, NH, S, and optionally two carbons together may form a double bond; (e) Y is selected from the group consisting of C, O, S, NH and a single bond; and (f) E is selected from the group consisting of C(R3) (R4)A, A, and a substituted or unsubstituted group selected from the group consisting of (CH 2 )n COOR19.

  本发明涉及以下结构式(I)所表示的化合物，其中：(a) R1选自氢、C1-C8烷基、芳基-C0-4-烷基、杂芳基-C0-4-烷基、C6环烷基芳基-C0-2-烷基和—CH2—C(O)—R17-R18的取代或未取代基团，其中R17为O或NH，R18为可选的取代苯基；(b) R2选自C1-C6烷基、C1-C6烯基、芳基-C0-4-烷基、杂芳基-C0-4-烷基、C1-C4烷基磺酰胺、C1-C4烷基酰胺、OR10和C3-C6环烷基；(c) W为O或S；(d) X为可选取代的C1-C5烷基链，其中链的一个碳原子可选地被O、NH、S替换，可选地两个碳原子可以形成双键；(e) Y选自C、O、S、NH和单键；(f) E选自C(R3)(R4)A、A和取代或未取代的(CH2)nCOOR19基团。
• Modulators of peroxisome proliferator activated receptors
  申请人：Brooks Alisa Dawn

  公开号：US20050020684A1

  公开（公告）日：2005-01-27

  Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, —CH 2 — or —CH 2 CH 2 —; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length. Phenyl Ring A is optionally substituted with up to four substituents in addition to R 1 and W, R 2 is (CH 2 ) n —CH(OR 2 )—(CH 2 ) n E, —(CH)═C(OR 2 )—(CH 2 ) n E, —(CH 2 ) n —CH(Y)—(CH 2 ) m E or (CH)═C(Y)(CH 2 ) m E; wherein E is COOR 3 , C 1 -C 3 alkylnitrile, carboxamide, sulfonamide, acylsulfonamide or tetrazole and wherein sulfonamide, acylsulfonamide and tetrazole are optionally substituted with one or more substituents independently selected from: C 1 -C 6 alkyl, haloalkyl and aryl-C o - 4 -alkyl; R 2 is H, an aliphatic group, a substituted aliphatic group, haloalkyl, an aromatic group, a substituted aromatic group, —COR 4 , —COOR 4 , —CONR 5 R 6 , —C(S)R 4 , —C(S)OR 4 or C(S)NR 5 R 6 , R 3 is H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. Y is O—, CH 2 —, CH 2 CH 2 — or CH═CH— and is bonded to a carbon atom in Phenyl Ring A that is ortho to R 1 . R 4 -R 6 are independently H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. n and m are independently 0, 1 or 2.

  本发明公开了一种由结构式（I）表示的化合物：其中Ar是取代或未取代的芳香基团。Q是共价键，-CH2-或-CH2CH2-; W是取代或未取代的烷基或取代或未取代的异烷基连接基，长度为两到十个原子，优选长度为两到七个原子。苯环A可选地与R1和W以外的最多四个取代基取代，R2是（CH2）n-CH（OR2）-（CH2）nE，-（CH）=C（OR2）-（CH2）nE，-（CH2）n-CH（Y）-（CH2）mE或（CH）=C（Y）（CH2）mE;其中E是COOR3，C1-C3烷基腈，羧酰胺，磺酰胺，酰基磺酰胺或四唑，磺酰胺，酰基磺酰胺和四唑可选地与一个或多个取代基取代，独立地选自：C1-C6烷基，卤代烷基和芳基-Co-4-烷基; R2是H，脂肪基，取代脂肪基，卤代烷基，芳基，取代芳基，-COR4，-COOR4，-CONR5R6，-C（S）R4，-C（S）OR4或C（S）NR5R6，R3是H，脂肪基，取代脂肪基，芳基或取代芳基。Y是O-，CH2-，CH2CH2-或CH═CH-，并与Phenyl环A中与R1相邻的碳原子键合。R4-R6独立地是H，脂肪基，取代脂肪基，芳基或取代芳基。n和m独立地为0、1或2。
• CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF
  申请人：Eisai Co., Ltd.

  公开号：EP1380562A1

  公开（公告）日：2004-01-14

  The present invention provides a novel carboxylic acid compound, a salt thereof or a hydrate of them useful as an insulin sensitizer, and a medicament comprising the compound as an active ingredient. That is, the present invention provides a carboxylic acid compound represented by the following formula, a salt thereof, an ester thereof or a hydrate of them. Wherein R1 represents a hydrogen atom, hydroxyl group, halogen, carboxyl group, or a C1-6 alkyl group etc., each of which may have one or more substituents; L represents a single bond, or a C1-6 alkylene group, a C2-6 alkenylene group or a C2-6 alkynylene group, each of which may have one or more substituents; M represents a single bond, or a C1-6 alkylene group, a C2-6 alkenylene group or a C2-6 alkynylene group, each of which may have one or more substituents; T represents a single bond, or a C1-3 alkylene group, a C2-3 alkenylene group or a C2-3 alkynylene group, each of which may have one or more substituents; W represents a carboxyl group; - - - represents a single bond etc. ; X represents a single bond, oxygen atom, a group represented by -NRX1CQ1O- (wherein Q1 represents an oxygen atom or sulfur atom; and RX1 represents a hydrogen atom, formyl group, or a C1-6 alkyl group etc., each of which may have one or more substituents), -OCQ1NRX1- (wherein Q1 and RX1 are as defined above), -CQ1NRx1O- (wherein Q1 and RX1 are as def ined above), ONRX1CQ1- (wherein Q1 and RX1 are as defined above), - Q2SO2- (wherein Q2 is an oxygen atom or -NRX10- (wherein RX10 represents a hydrogen atom, formyl group, or a C1-6 alkyl group etc., each of which may have one or more substituents)) or -SO2Q2- (wherein Q2 is as defined above), (wherein, provided that RX2 and RX3, and/or RX4 and RX5 may together form a ring, Q3 and Q4 are the same as or different from each other and each represents an oxygen atom, (O)S(O) or NRX10 (wherein NRX10 is as defined above)); Y represents a 5- to 14-membered aromatic group etc., which may have one or more substituents and one or more hetero atoms; and the ring Z represents a 5-to 14-membered aromatic group which may have 0 to 4 substituents and one or more hetero atoms, and wherein part of the ring may be saturated.

  本发明提供了一种可用作胰岛素增敏剂的新型羧酸化合物、其盐或其水合物，以及包含该化合物作为活性成分的药物。也就是说，本发明提供了由下式代表的羧酸化合物、其盐、其酯或它们的水合物。 其中 R1 代表氢原子、羟基、卤素、羧基或 C1-6 烷基等、L 代表单键，或 C1-6 亚烷基、C2-6 亚烯基或 C2-6 亚炔基，其中每个基团可带有一个或多个取代基；M 代表单键，或 C1-6 亚烷基、C2-6 亚烯基或 C2-6 亚炔基，其中每个基团可有一个或多个取代基； T 代表单键，或 C1-3 亚烷基、C2-3 亚烯基或 C2-3 亚炔基，其中每个基团可有一个或多个取代基； W 代表羧基； - - - 代表单键等；X 代表单键、氧原子、由 -NRX1CQ1O- 代表的基团（其中 Q1 代表氧原子或硫原子；RX1 代表氢原子、甲酰基或 C1-6 烷基等）、其中每个取代基可有一个或多个）、-OCQ1NRX1-（其中 Q1 和 RX1 如上定义）、-CQ1NRx1O-（其中 Q1 和 RX1 如上定义）、ONRX1CQ1-（其中 Q1 和 RX1 如上定义）、-Q2SO2-（其中 Q2 是氧原子或-NRX10-（其中 RX10 代表氢原子、甲酰基或 C1-6 烷基等、其中每个基团可具有一个或多个取代基））或-SO2Q2-（其中 Q2 如上定义）、 (其中，只要 RX2 和 RX3，和/或 RX4 和 RX5 可共同形成一个环，Q3 和 Q4 彼此相同或不同，且各自代表氧原子、（O）S（O）或 NRX10（其中 NRX10 如上定义））；Y 代表 5 至 14 元芳香基团等、环 Z 代表 5 至 14 元芳香基团，可具有 0 至 4 个取代基和一个或多个杂原子，其中部分环可为饱和环。